|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���Ī�� |
|
����,���� |
|
����ʪ�� |
|
���ż��� |
| ��������������� | |
|
�⽣�� |
|
֣���� |
| PubMed | |
|
Article by |
|
Article by |
���Ī�ص�ʵ�������ٴ��о���չ
�⽣��, ֣����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
���Ī����һ��С�������ߵ��ڼ�,��ͨ����ϸ�������Toll��������,�յ�����ϸ�����ڶ���ϸ������,������������Ȼ����������ϵͳ,���ӿ������������������ߵ��ڻ��ԡ�Ŀǰ���Ī���ѳɹ����Ƹ�����ֳ���༰�������������Ƥ�����������������Ч�������Ƥ����,���Ī�ؾ����ܾ���DZ�ڵ����Ƽ�ֵ��
[2] Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother, 2001,45 (4):1137-1142.
[3] Bums RP Jr, Ferbel B, Tomai M,et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol, 2000, 94(1):13-23.
[4] Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R 848 and imiquimod. Cell Immunol, 1999, 191 (1):10-19.
[5] Bishop GA, Ramirez LM, Baccam M, et al. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol, 2001, 208(1):9-17.
[6] Hemmi H, Kaisho T, Takeuchi O,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 2002, 3 (2):196-200.
[7] Soria I, Myhre P, Horton V, et al. Effect of food on the pharmacoki netics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther, 2000, 38(10):476-481.
[8] Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and peri anal warts. Prim. Care Update Ob Gyns, 1998, 5(4):151.
[9] Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother, 1998, 42(4):789-794.
[10] Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imi quimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis, 1998, 178 (3):858-861.
[11] Savage P, Horton V, Moore J, et al. A phase I clinical trial of imi quimod, an oral interferon inducer, administered daily. Br J Cancer, 1996, 74(9):1482-1486.
[12] Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol, 1998, 38(2 Pt 1):230-239.
[13] Garland SM, Sellors JW, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label, multicentre Phase ��B trial. Int J STD AIDS, 2001, 12(11):722-729.
[14] Moore RA, Edwards JE, Hopwood J,et al. Imiquimod for the treat ment of genital warts:a quantitative systematic review. BMC Infect Dis, 2001,1(1):3.
[15] Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res, 1999, 43 (1):55-63.
[16] Arrese J, Paquet P, Claessens N, et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001,28(3):131-134.
[17] Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for mollus cum contagiosum. J Cutan Med Surg, 2000, 4(2):76-82.
[18] Schacker TW, Conant M, Thoming C, et al. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis:a phase ��, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother, 2002, 46(10):3243-3248.
[19] Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%:a report of six cases. Br J Dermatol, 2001, 144(5):1050-1053.
[20] Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol, 2002, 85(1):67-70.
[21] Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imi quimod 5% cream and a cox inhibitor, sulindac:potential applications for this combination of immunotherapy. Dermatol Surg, 2001, 27(2):143-146.
[22] Mackenzie-Wood A, Kossard S, de Launey J,et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol, 2001,44(3):462-470.
[23] Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma:results of a multicenter 6-week dose-response trial. J Am Acad Dermatol, 2001,44(5):807-813.
[24] Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma:a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol, 2002, 47 (3):390-398.
[25] Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology, 2002, 205 (2):135-138.